FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer

RAHWAY, N.J.--(BUSINESS WIRE)--Dec 15, 2023--

Related Keywords

Canada ,United States ,Julie Cunningham ,Seagen Padcev ,Peter Dannenbaum ,Damini Chokshi ,Chrissy Trank ,Youtube ,European Society For Medical Oncology Congress ,Patient Support Program ,Facebook ,Statement Of Merck Co Inc ,Pfizer Inc ,Agensys Inc ,Exchange Commission ,Pfizer ,Twitter ,Merck Access Program ,Seagen Inc ,Merck Co Inc ,Drug Administration ,Instagram ,Linkedin ,Merck Patient Support Program ,European Society ,Medical Oncology Congress ,Presidential Symposium ,Time Oncology Review ,Bacillus Calmette Guerin ,Selected Important Safety ,Important Safety Information ,Fatal Immune Mediated Adverse ,Which Can Present With Diabetic ,Nervous System ,Connective Tissue ,Patients With Multiple ,Neck Squamous Cell ,Mismatch Repair Deficient ,Mismatch Repair Deficient Colorectal ,Support Program ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Prescribing Information ,Medication Guide ,Media Contacts ,Business Wire ,Region ,